HILL: The efficacy and safety of hepatic arterial infusion chemotherapy with FOLFOX regimen combine lenvatinib and durvalumab in unresectable hepatocellular carcinoma: A prospective, phase II, single-armed, clinical trial

被引：0
|
作者：
Li, S. [1 ]
Lu, L. [1 ]
Wang, Q. [2 ]
Zhao, R. [3 ]
Mei, J. [1 ]
Li, J-B. [4 ]
Zheng, L. [5 ]
Wei, W. [3 ]
Guo, R. [3 ]
机构：
[1] Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Liver Surg, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ Canc Ctr, Radiat Oncol, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ Canc Ctr, Liver Surg, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ Canc Ctr, Clin Res, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ Canc Ctr, Dept Imaging, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1042
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
982P
引用
收藏
页码：S670 / S671
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study.
    Xu, Yongkang
    Fu, Shumin
    Mao, Ye
    Yi, Fengming
    Jiang, Weiming
    Feng, Long
    Wu, Jianbing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 500 - 500
  • [2] Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma
    Zhao, Rongce
    Zhou, Jing
    Miao, Zhaoxia
    Xiong, Xinhao
    Wei, Wei
    Li, Shaohua
    Guo, Rongping
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [3] Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma
    Zhao, Rongce
    Zhou, Jing
    Li, Shaohua
    Wei, Wei
    Guo, Rongping
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Efficacy and safety of hepatic arterial infusion chemotherapy combined with donafenib in the treatment of unresectable hepatocellular carcinoma
    Wan, Tao
    Gan, Xueqin
    Xiong, Weijie
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 (06) : 747 - 753
  • [5] The efficacy and safety of transarterial chemoembolization combined with cadonilimab and lenvatinib for unresectable hepatocellular carcinoma: A phase II clinical trial
    Liang, Guo
    Gu, Shanzhi
    Guo, Yabing
    Li, Hailiang
    Liu, Jingfeng
    Liu, Jibing
    Huang, Ming
    Zou, Yinghua
    Huang, Luke
    Zhang, Yangyang
    Liu, Ting
    Liu, Wei
    Wang, Zhongmin
    Li, Baiyong
    Xia, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 478 - 478
  • [6] A retrospective study exploring the safety and efficacy of hepatic arterial infusion chemotherapy and sequential transarterial embolization combined with lenvatinib and tislelizumab in unresectable hepatocellular carcinoma
    Zhong, Jian-Hong
    Chen, Zu-Shun
    Qi, Lu-Nan
    Zhang, Zhi-Ming
    Xiang, Bang-De
    Ma, Liang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Hepatic arterial infusion chemotherapy sequential transarterial embolization combined with lenvatinib and tislelizumab in patients with high-risk unresectable hepatocellular carcinoma: A phase II trial
    Zhong, J-H.
    Deng, Z.
    Qi, L-N.
    Chen, Z-S.
    Zhang, Z-M.
    Xiang, B.
    Ma, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S1484 - S1484
  • [8] Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma
    Liu, Yulong
    Qiao, Yansong
    Zhou, Miaoli
    Guo, Jiandong
    Lin, Yinsheng
    Li, Wanghai
    An, Chao
    Li, Chengzhi
    CANCER MEDICINE, 2023, 12 (05): : 5436 - 5449
  • [9] Hepatic arterial infusion chemotherapy (HAIC) combined with Tislelizumab and Lenvatinib for unresectable hepatocellular carcinoma: a retrospective single-arm study
    Sun, Ruirui
    Gou, Yang
    Pan, Long
    He, Qiang
    Zhou, Yin
    Luo, Yi
    Wu, Chenrui
    Zhao, Yaowu
    Fu, Zixuan
    Huang, Ping
    CELLULAR ONCOLOGY, 2024,
  • [10] Multicenter Phase II trial of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: LEOPARD
    Ikeda, Masafumi
    Yamashita, Tatsuya
    Ogasawara, Sadahisa
    Kudo, Masatoshi
    Inaba, Yoshitaka
    Morimoto, Manabu
    Tsuchiya, Kaoru
    Shimizu, Satoshi
    Kojima, Yasushi
    Hiraoka, Atsushi
    Nouso, Kazuhiro
    Aikata, Hiroshi
    Numata, Kazushi
    Sato, Tosiya
    Okusaka, Takuji
    Furuse, Junji
    LIVER CANCER, 2024, 13 (02) : 193 - 202
12345